The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide

PLoS Neglected Tropical Diseases

Volumn 6, Issue 1, 2012, Pages

  Tuanyok, Apichai ^a   Stone, Joshua K ^a   Mayo, Mark ^b   Kaestli, Mirjam ^b   Gruendike, Jeffrey ^a   Georgia, Shalamar ^a   Warrington, Stephanie ^a   Mullins, Travis ^a   Allender, Christopher J ^a   Wagner, David M ^a   Chantratita, Narisara ^c   Peacock, Sharon J ^c   Currie, Bart J ^b   Keim, Paul ^a,d  

^a NORTHERN ARIZONA UNIVERSITY   (United States)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; O ANTIGEN; BACTERIAL DNA; LIPOPOLYSACCHARIDE;

ANTIGEN SPECIFICITY; ARTICLE; BIOINFORMATICS; BURKHOLDERIA PSEUDOMALLEI; DNA SEQUENCE; GENE CLUSTER; GENETIC VARIABILITY; GENOTYPE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANTIGENIC VARIATION; AUSTRALIA; BIOLOGY; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MELIOIDOSIS; METHODOLOGY; MICROBIOLOGY; MOLECULAR GENETICS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SOUTHEAST ASIA;

ANTIGENIC VARIATION; ASIA, SOUTHEASTERN; AUSTRALIA; BURKHOLDERIA PSEUDOMALLEI; COMPUTATIONAL BIOLOGY; DNA, BACTERIAL; GENOTYPE; HUMANS; LIPOPOLYSACCHARIDES; MELIOIDOSIS; MOLECULAR SEQUENCE DATA; MULTIPLEX POLYMERASE CHAIN REACTION; O ANTIGENS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 84856569017     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001453     Document Type: Article

References (30)

1. Caroff M, Karibian D, (2003) Structure of bacterial lipopolysaccharides. Carbohyd Res 338: 2431-2447.
2. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, et al. (2004) Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. Journal of Medical Microbiology 53: 1177-1182.
3. Sarkar-Tyson M, Thwaite JE, Harding SV, Smither SJ, Oyston PCF, et al. (2007) Polysaccharides and virulence of Burkholderia pseudomallei. Journal of Medical Microbiology 56: 1005-1010.
4. DeShazer D, Brett PJ, Woods DE, (1998) The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Molecular Microbiology 30: 1081-1100.
5. Leon CG, Tory R, Jia J, Sivak O, Wasan KM, (2008) Discovery and development of Toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharmaceutical Research 25: 1751-1761.
6. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, et al. (2010) Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg 82: 1113-1117.
7. Charuchaimontri C, Suputtamongkol Y, Nilakul C, Chaowagul W, Chetchotisakd P, et al. (1999) Antilipopolysaccharide II: An antibody protective against fatal melioidosis. Clinical Infectious Diseases 29: 813-818.
8. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, et al. (1997) Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infection and Immunity 65: 3648-3653.
9. Arjcharoen S, Wikraiphat C, Pudla M, Limposuwan K, Woods DE, et al. (2007) Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: Possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infection and Immunity 75: 4298-4304.
10. Anuntagool N, Wuthiekanun V, White NJ, Currie BJ, Sermswan RW, et al. (2006) Short report: Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. American Journal of Tropical Medicine and Hygiene 74: 348-352.
11. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M, (1995) Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infection and Immunity 63: 3348-3352.
12. Ngugi SA, Ventura VV, Qazi O, Harding SV, Kitto GB, et al. (2010) Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine 28: 7551-7555.
13. Burtnick MN, Deshazer D, Woods DE, (2002) Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol 184: 849-852.
14. Brett PJ, Burtnick MN, Heiss C, Azadi P, DeShazer D, et al. (2011) Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides. Infection and Immunity 79: 961-969.
15. Tuanyok A, Leadem BR, Auerbach RK, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, et al. (2008) Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics 9: 566.
16. Tuanyok A, Auerbach RK, Brettin TS, Bruce DC, Munk AC, et al. (2007) A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol 189: 9044-9049.
17. U' Ren JM, Schupp JM, Pearson T, Hornstra H, Clark CL, et al. (2007) Large tanden repeat regions within Burkholderia pseudomallei genome and their application for high resolution genotyping. BMC Microbiology 7: 23.
18. Chantratita N, Wuthiekanun V, Boonbumrung K, Tiyawisutsri R, Vesaratchavest M, et al. (2007) Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol 189: 807-817.
19. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-416.
20. Currie BJ, Ward L, Cheng AC, (2010) The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 4: e900.
21. Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, et al. (2005) ACT: the Artemis Comparison Tool. Bioinformatics 21: 3422-3423.
22. Gee JE, Glass MB, Novak RT, Gal D, Mayo MJ, et al. (2008) Recovery of a Burkholderia thailandensis-like isolate from an Australian water source. BMC Microbiol 8: 54.
23. Wuthiekanun V, Anuntagool N, White NJ, Sirisinha S, (2002) Short report: A rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg 66: 759-761.
24. Qazi O, Prior JL, Judy BM, Whitlock GC, Kitto GB, et al. (2008) Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Trans R Soc Trop Med Hyg 102: S58-60.
25. Novem V, Shui GH, Wang DL, Bendt AK, Sim SH, et al. (2009) Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clinical and Vaccine Immunology 16: 1420-1428.
26. Nussbaum JJ, Hull DS, Carter MJ, (1980) Pseudomonas pseudomallei in an anopthalmic orbit. Arch Opthalmol 98: 1224-1225.
27. Arjcharoen S, Wikraiphat C, Pudla M, Limposuwan K, Woods DE, et al. (2007) Fate of a Burkholderia pseudomallei mouse macrophage cell line lipopolysaccharide mutant in the RAW 264.7: Possible role for the o-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infection and Immunity 75: 4298-4304.
28. Wikraiphat C, Charoensap J, Utaisincharoen P, Wongratanacheewin S, Taweechaisupapong S, et al. (2009) Comparative in vivo and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using lipopolysaccharide, capsule and flagellin mutants. FEMS Immunol Med Microbiol 56: 253-259.
29. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, et al. (2007) Toll-like receptor 2 impairs host defense in Gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Medicine 4: e248.
30. West TE, Ernst RK, Jansson-Hutson MJ, Skerrett SJ, (2008) Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunology 9.